Key Takeaways
- Co-Diagnostics (CODX) stock surged 9.43% to reach $2.90 during Friday’s premarket session
- CoSara Diagnostics, the company’s Indian joint venture, secured territorial rights to distribute products across Bangladesh, Pakistan, Nepal, and Sri Lanka
- The regional expansion increases CoSara’s total addressable market across South Asia to approximately $13 billion
- Key products slated for these markets include the PCR Pro® point-of-care device and SARAGENE® diagnostic products, subject to local regulatory clearances
- CoSara is preparing a virtual distributor briefing in Q2 2026 followed by an in-person training event later in the summer
Shares of Co-Diagnostics (CODX) surged 9.43% to $2.90 during Friday’s premarket session following news of a significant geographic expansion for the company’s South Asian operations.
CoSara Diagnostics Pvt. Ltd., a collaborative venture between Co-Diagnostics and Ambalal Sarabhai Enterprises Limited (ASE Group), has finalized an agreement expanding its territorial footprint throughout South Asia. The expansion encompasses Bangladesh, Pakistan, Nepal, and Sri Lanka.
This strategic move expands CoSara’s estimated addressable market opportunity in the region to approximately $13 billion, according to company calculations incorporating internal research and external market intelligence.
The territorial agreement aims to facilitate the launch of two primary product offerings: the CoSara PCR Pro® point-of-care diagnostic system and the SARAGENE® testing portfolio. Market entry for both platforms remains contingent upon obtaining necessary regulatory authorizations in each jurisdiction.
CoSara has initiated efforts to develop distribution infrastructure throughout the four target countries. This process encompasses navigating regulatory frameworks, pinpointing priority customer groups, and forging relationships with regional distribution partners.
Executive Perspectives on Strategic Expansion
Mohal Sarabhai, Chief Executive of CoSara, highlighted the substantial and expanding demand throughout South Asia for convenient, non-invasive molecular diagnostic solutions. He specifically cited tuberculosis screening, HPV detection, and respiratory pathogen testing as critical application areas.
Dwight Egan, CEO of Co-Diagnostics, positioned the agreement within the company’s broader infrastructure-centric expansion approach. The strategy emphasizes establishing regional manufacturing capabilities and distribution networks ahead of commercial launches—a methodology being implemented across the United States, South Asia, and the Middle East-North Africa region.
Egan emphasized that this groundwork is designed to enable scalable worldwide deployment of Co-Diagnostics’ PCR point-of-care technology platform.
To facilitate distributor recruitment, CoSara will conduct a virtual information and training session during Q2 2026. This will be followed by a face-to-face distributor conference and comprehensive training program scheduled for later that summer.
Current Stock Performance Context
Prior to Friday’s rally, CODX was hovering near its 52-week floor of $2.04. The 9.43% premarket surge lifted shares to $2.90.
Investors should note that the PCR Pro® platform and associated diagnostic products remain under FDA evaluation and are not currently commercially available.
Earlier in March, Co-Diagnostics secured Japanese patent protection for its PCR platform innovations. Previously, the company successfully resolved NASDAQ compliance concerns related to its continued listing eligibility.
The $13 billion total addressable market projection relies on proprietary analysis combined with third-party market research. Realized revenue generation will ultimately depend on regulatory success and the effectiveness of distributor development efforts across all four expansion territories.
